Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Bevacizumab 32Cetuximab 28Fluorouracil 26Leucovorin 24Specimen Handling 23Oxaliplatin 23pembrolizumab 18Biopsy 16Magnetic Resonance Spectroscopy 14Irinotecan 13Nivolumab 9atezolizumab 7Folfox protocol 7fludarabine 6balstilimab 6Pemetrexed 6Panitumumab 6Cyclophosphamide 6Cisplatin 6Carboplatin 6Capecitabine 6trifluridine tipiracil drug combination 5encorafenib 5Standard of Care 5IFL protocol 5HMPL-013 5Gemcitabine 5dehydroftorafur 4Immunoglobulin G 4Disulfides 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Embolization, Therapeutic × 30 days × Clear all
NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Mayo Clinic

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡